Table 2.

Entities associated with cytotoxic lesions of the corpus callosum (CLOCC) in adults

Drug or drug withdrawal or toxins (n = 88) (27%)	Antiepileptic (n = 32) Neuroleptic (n = 12) Carbamazepine (n = 8) Chemotherapy (n = 8) Dietary supplement (n = 6) Metronidazole (n = 6) Immunomodulary drugs (n = 4) Toxins (n = 4) Other (n = 6)
Vascular (n = 60) (18%)	Subarachnoid hemorrhage (n = 49) Stroke (n = 1) Other (n = 10)
Viral (n = 59) (18%)	COVID-19 (n = 15) Influenza virus (n = 13) Dengue virus (n = 5) Epstein-Barr virus (n = 4) Other (n = 22)
Bacteria and plasmodia (n = 34) (10%)	Plasmodium falciparum (n = 8) Mycoplasma pneumoniae (n = 7) Staphlyococcus aureus (n = 4) other (n = 15)
Seizure and epilepsy (n = 20) (6%)	Status epilepticus (n = 1) Other (n = 19)
Metabolic (n = 10) (3%)	Hypo- and hyperglycemia (n = 10)
Pregnancy-associated (n = 8) (2%)	Eclampsia (n = 1) other (n = 7)
Autoimmune (n = 6) (2%)	GFAP antibodies (n = 2) Anti-NMDA encephalitis (n = 1) SLE (n = 1) Other (n = 2)
Traumatic (n = 4) (1%)	Head trauma (n = 4)
Neoplasia (n = 4) (1%)	Insulinoma (n = 1) Leukemia (n = 1) Mantle cell lymphoma (n = 1) Melanocytoma (n = 1)
Various causes (n = 37) (11%)	Alcoholism (n = 1) COVID-19 vaccine (n = 1) Deep brain stimulation (n = 1) High-altitude sickness (n = 1) Migraine (n = 1) Parkinsonism (n = 1) Other (n = 31)

In 330 adult patients, an associated disease was identified; in 86 patients, no associated disease entity could be identified (number of subjects per associated disease is reported in brackets). Only diseases which occurred more than once or deemed of special interest are listed in this table, for a detailed list see supplementary data

Anti-NMDA encephalitis anti-N-methyl-d-aspartate-receptor encephalitis, GFAP antibodies glial fibrillary acidic protein antibodies, SLE systemic lupus erythematosus